Literature DB >> 22526270

Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT.

Tatsuo Inoue1, Masatoshi Kudo, Mina Komuta, Sosuke Hayaishi, Taisuke Ueda, Masahiro Takita, Satoshi Kitai, Kinuyo Hatanaka, Norihisa Yada, Satoru Hagiwara, Hobyung Chung, Toshiharu Sakurai, Kazuomi Ueshima, Michiie Sakamoto, Osamu Maenishi, Tomoko Hyodo, Masahiro Okada, Seishi Kumano, Takamichi Murakami.   

Abstract

BACKGROUND: We aimed to evaluate gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) for the detection of hepatocellular carcinomas (HCCs) and dysplastic nodules (DNs) compared with dynamic multi-detector row computed tomography (MDCT), and to discriminate between HCCs and DNs.
METHODS: Eighty-six nodules diagnosed as HCC or DNs were retrospectively investigated. Gd-EOB-DTPA-enhanced MRI and dynamic MDCT were compared with respect to their diagnostic ability for hypervascular HCCs and detection sensitivity for hypovascular tumors. The ability of hepatobiliary images of Gd-EOB-DTPA-enhanced MRI to discriminate between these nodules was assessed. We also calculated the EOB enhancement ratio of the tumors.
RESULTS: For hypervascular HCCs, the diagnostic ability of Gd-EOB-DTPA-enhanced MRI was significantly higher than that of MDCT for tumors less than 2 cm (p = 0.048). There was no difference in the detection of hypervascular HCCs between hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI (43/45: 96%) and dynamic MDCT (40/45: 89%), whereas the detection sensitivity of hypovascular tumors by Gd-EOB-DTPA-enhanced MRI was significantly higher than that by dynamic MDCT (39/41: 95% vs. 25/41: 61%, p = 0.001). EOB enhancement ratios were decreased in parallel with the degree of differentiation in DNs and HCCs, although there was no difference between DNs and hypovascular well-differentiated HCCs.
CONCLUSION: The diagnostic ability of Gd-EOB-DTPA-enhanced MRI for hypervascular HCCs less than 2 cm was significantly higher than that of MDCT. For hypovascular tumors, the detection sensitivity of hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI was significantly higher than that of dynamic Gd-EOB-DTPA-enhanced MRI and dynamic MDCT. It was difficult to distinguish between DNs and hypovascular well-differentiated HCCs based on the EOB enhancement ratio.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526270     DOI: 10.1007/s00535-012-0571-6

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  23 in total

1.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.

Authors:  Luca Di Tommaso; Giada Franchi; Young Nyun Park; Barbara Fiamengo; Annarita Destro; Emanuela Morenghi; Marco Montorsi; Guido Torzilli; Maurizio Tommasini; Luigi Terracciano; Luigi Tornillo; Raffaella Vecchione; Massimo Roncalli
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

2.  Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow.

Authors:  Sachiyo Kogita; Yasuharu Imai; Masahiro Okada; Tonsok Kim; Hiromitsu Onishi; Manabu Takamura; Kazuto Fukuda; Takumi Igura; Yoshiyuki Sawai; Osakuni Morimoto; Masatoshi Hori; Hiroaki Nagano; Kenichi Wakasa; Norio Hayashi; Takamichi Murakami
Journal:  Eur Radiol       Date:  2010-05-19       Impact factor: 5.315

3.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

Review 4.  Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions.

Authors:  M Kudo
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 5.  Multistep human hepatocarcinogenesis: correlation of imaging with pathology.

Authors:  Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

6.  Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography.

Authors:  Young Kon Kim; Chong Soo Kim; Young Min Han; Hyo Sung Kwak; Gong Yong Jin; Seung Bae Hwang; Gyung Ho Chung; Sang Yong Lee; Hee Chul Yu
Journal:  J Comput Assist Tomogr       Date:  2009 Nov-Dec       Impact factor: 1.826

7.  Early hepatocellular carcinoma: appearance at CT during arterial portography and CT arteriography with pathologic correlation.

Authors:  K Takayasu; Y Muramatsu; H Furukawa; F Wakao; N Moriyama; T Takayama; S Yamasaki; M Sakamoto; S Hirohashi
Journal:  Radiology       Date:  1995-01       Impact factor: 11.105

8.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Authors:  Seong Hyun Kim; Seung Hoon Kim; Jongmee Lee; Min Ju Kim; Yong Hwan Jeon; Yulri Park; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

9.  Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material.

Authors:  Makiko Hayashi; Osamu Matsui; Kazuhiko Ueda; Yasuhiro Kawamori; Toshifumi Gabata; Masumi Kadoya
Journal:  Radiology       Date:  2002-10       Impact factor: 11.105

10.  Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images.

Authors:  Tatsuo Inoue; Masatoshi Kudo; Ryousuke Watai; Zhou Pei; Toshihiko Kawasaki; Yasunori Minami; Hobyung Chung; Toyokazu Fukunaga; Kazuo Awai; Osamu Maenishi
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 6.772

View more
  30 in total

1.  Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study.

Authors:  Tatsuo Inoue; Tomoko Hyodo; Keiko Korenaga; Takamichi Murakami; Yasuharu Imai; Atsushi Higaki; Takeshi Suda; Toru Takano; Kennichi Miyoshi; Masahiko Koda; Hironori Tanaka; Hiroko Iijima; Hironori Ochi; Masashi Hirooka; Kazushi Numata; Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2015-09-15       Impact factor: 7.527

Review 2.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 4.  Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Authors:  Alexander Kagen; Kathryn Fowler; Claude B Sirlin
Journal:  Hepat Oncol       Date:  2013-12-20

5.  Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis.

Authors:  Katsuhiro Sano; Tomoaki Ichikawa; Utaroh Motosugi; Shintaro Ichikawa; Hiroyuki Morisaka; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii
Journal:  Eur Radiol       Date:  2016-06-02       Impact factor: 5.315

Review 6.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

Review 7.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

8.  Quantitative assessment of hepatic function: modified look-locker inversion recovery (MOLLI) sequence for T1 mapping on Gd-EOB-DTPA-enhanced liver MR imaging.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Munyoung Paek; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

9.  Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012.

Authors:  Keisuke Amano; Takumi Kawaguchi; Ryoko Kuromatsu; Atsushi Kawaguchi; Ichiro Miyajima; Tatsuya Ide; Tatsuyuki Kakuma; Michio Sata
Journal:  Mol Clin Oncol       Date:  2014-08-21

Review 10.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.